A recent study indicates that patients who come off new slimming jabs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who halt conventional lifestyle plans.
Research printed in a prominent health publication shows that while obese individuals frequently drop a large proportion of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals using these treatments must be cognizant of the danger of fast weight regain when the treatment ends," warns researcher Dr. Susan Jebb.
This pace of regain means a return to starting weight in about 18 months.
Comparing Therapies
The research, which looked at dozens of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
Scientists point out that people who shed pounds through diet and exercise generally see a less rapid weight regain—perhaps 100 grams monthly—once they finish.
The Reason for the Quick Rebound
Nutrition scientists suggest the way of the jabs explains the accelerated weight return.
The injections mimic a natural hormone called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the body to produce less of its endogenous hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement leads to appetite is uncontrolled, making binge eating far more likely."
A Chronic Condition?
Medical guidelines suggest the injections for people with weight-linked health risks, alongside recommended lifestyle changes.
Many experts argue that, given the significant potential of relapse, the therapy should be considered long-term.
This perspective is reinforced by pharmaceutical companies, who say that the findings "underscore the persistent character of excess weight," similar to managing diseases like high blood pressure.
User Accounts
Individuals who have discontinued the medication explain a sudden return of appetite.
"It felt as if something flipping and you're instantly ravenous," said a patient.
This difficulty is worsened if users have not established sustainable dietary or behavioural modifications during therapy.
Growing Use
Survey data suggest that a significant number of people in the UK have tried these injections in the last 12 months, with desire remaining high.
- Adoption is higher among women compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while the jabs are powerful tools for shedding pounds, they are not a standalone cure and lasting health benefits likely depends on ongoing lifestyle management.
